Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Esteve“
Suchtreffer
Begriffe & Kennungen
Ketoconazole Esteve (previously Ketoconazole HRA)
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.1 Therapeutic indications · 1
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.3 Contraindications · 1
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.3 · - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1; - Hypersensitivi
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.3 · 4 o colchicine in patients with renal impairment due to an increased risk of severe adverse reactions; o irino
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.3 · The list above is not an inclusive list of compounds that may interact with ketoconazole and result in potenti
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · (CYP3A enzyme induction) Maraviroc Maraviroc: Careful monitoring. Maraviroc dose AUC: ↑ 5-fold should be decre
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · - Ketoconazole is a potent inhibitor of CYP3A4 and can inhibit the metabolism of medicinal products metabolise
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 10 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 12 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 13 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 14 * Rosuvastatin is not a CYP 3A4 substrate. Ketoconazole did not produce any change in rosuvastatin pharmaco
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 7 Potent inhibitors of CYP3A4 (e.g. antivirals such as ritonavir, ritonavir-boosted darunavir and ritonavir- b
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 8 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration D
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · 9 Medicinal product by Expected effect on drug levels Recommendation for co- therapeutic area administration T
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · Co-administration of ketoconazole and pasireotide is not recommended since the combination can lead to a QT pr
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · Concomitant therapy with medicinal products that are contraindicated during treatment with ketoconazole and re
Eintrag öffnenKetoconazole Esteve (previously Ketoconazole HRA) · 4.5 · Effects of ketoconazole on the metabolism of the other medicinal products
Eintrag öffnen